【新唐人2013年08月21日訊】外資醫藥企業在華行賄風波愈演愈烈，繼全球知名製藥廠商葛蘭素史克4名高管被刑拘後，阿斯利康、賽諾菲、禮來等藥業巨頭也爆出類似醜聞。媒體報導揭示，很多跨國藥企在進入中國後，很快被「入鄉隨俗」，熱衷於「灰色營銷手法」，爭相招納中共高乾子弟作為企業高管。下面請看報導。
大陸媒體《證券市場週刊》最近披露了一份資料，羅列了部分在華跨國藥企的高管名單。其中，家世顯赫的李振福2003年加盟諾華公司任中國區總裁，此後諾華中國區的增長速度高達諾華全球增速的3倍。2012年接任諾華中國區總裁的徐海瑛則有一個家族背景很深的丈夫。
在這些跨國藥企的高管中，有些人還曾擔任過中共政協委員和人大代表。
馮丹龍，現任美國輝瑞製藥中國企業事務部總監、公司發言人，曾擔任全國政協委員、上海市人大代表。馮丹龍的姑姑馮理達是國內外著名免疫學專家，奶奶李德全則是中共建政後的首任衛生部部長。
大陸企業觀察員何軍樵向《新唐人》表示，中國大陸是一個專制的市場經濟社會，和其他自由社會的經濟形式都不一樣。
大陸企業觀察員何軍樵：「在這樣一個權力主導下的經濟結構裡面，經濟尋求與權力的這種合作，那是很自然的一個事情。所以運用這些高乾子弟，實際上也是考慮到他們背後的家庭背景關係。」
《證券市場週刊》的報導指出，跨國藥企在中國的經營已經披上政治色彩。跨國公司要想在中國新設或者併購企業等都需要各級政府部門的審批登記。因此，跨國藥企為了自身的經營和安全考慮，便把政府關係作為一項最主要工作，每年撥出大筆費用進行政府公關。於是，在這些跨國藥企負責與政府打交道的部門中，就出現了各種有深厚背景的人物。
北京國情內參首席研究員、獨立中國問題學家鞏勝利：「因為中國是一個人治的國家。人家說的紅二代、紅三代，一般都掌握有政治資源，政治資源簡單的說，就是批錢。那麼他一句話，通過他的關係（錢）進去到哪個企業，這都是很簡單的一件事。」
大陸網絡上，很多網民也對跨國藥企風波深有感觸。
有網友表示：再好的外企進入中國都會變質。網友寫道：權力迷藥天下無敵，無論本國、跨國（企業），盡入二代三代之手。
也有網友對中共當局近年進行的所謂「醫療改革」表示不滿。
新疆網友張先生：「它盛行潛規則。然後它通過中共權貴階層、太子黨代理以後，把藥價提得很高，即使國家給報銷一部分，老百姓的負擔也是比醫療改革以前還是增加了幾倍的負擔。」
據悉，跨國製藥企業進入中國已超過30年，目前，中國是僅次於美國和日本的全球第三大藥品市場。但這個市場卻因為中國的黨政體製而處處充滿腐敗的利益鏈條。
鞏勝利：「因為中國的社會允許這種腐敗存在，特別是黨政幹部。你像是黨的幹部，幾乎是說話一言九鼎，它沒有社會的製衡環境，沒有老百姓的監督環境。」
北京獨立中國問題學家鞏勝利指出，以前中共還提到過所謂「法治國家」，現在當局則一直在強調要加強黨治。而加強黨治自然就會把法治放到一邊，使人治更加強盛，腐敗更加嚴重。
採訪/朱智善 編輯/李謙 後製/王明宇
Multinational Pharmaceutical Companies in China Benefit Privilege Group
The corruption scandal of foreign pharmaceutical companies in China has intensified. Since the arrests of four senior managers at the world's leading pharmaceutical company GlaxoSmithKline,, AstraZeneca, Sanofi and Eli Lilly companies experienced similar scandals.
According to media reports, after multinational pharmaceutical companies enter China, they soon “do what Romans do”. They get keen on gray marketing practices. They recruit high-ranking officials' children to operate their businesses.
China's Capital Week magazine listed senior managers in multinational pharmaceutical companies in China. Among them, the distinguished lineage of Li Zhenfu (Jeffrey Li) joined Novartis in 2003, serving as China region President. Soon, the Novartis growth rate in China increased three times higher than the Novartis global market. In 2012, Xu Haiying became the Novartis president in China. Xu's husband came from a family with a connected background.
Among the list, some people in the past were members of the national committee and the National People's Congress
Feng Danlong currently serves as Affairs Director and spokesman of the US Pfizer China Corporate. Feng was a member of China's National Committee and a representative of Shanghai People's Congress. Feng's aunt Feng Lida was a famous immunology expert at home and abroad. Feng's grandmother, Li Dequan was the first Health Minister after the Chinese Communist Party (CCP) took over China.
He Junjiao, an enterprise observer in Mainland China told NTD that China is a society with authoritarian market. It has a different form comparing to free societys' economy.
He Junqiao: “Under such an economic structure, the economy latches onto the power becomes a natural outcome. Using high-ranking officials' children, actually is associated with their family background.”
Capital Week reported that multinational pharmaceutical companies in China have been involved in political affairs. If they want to set up or purchase a new company in China, they need CCP approval. Considering this point, they allocate relations with the CCP as their top priority work. They spend large amount of money on government relations. So these multinational pharmaceutical companies recruited people with well connected CCP backgrounds.
Gong Shenli, independent China affairs expert:“China is a country of men. The Red second and third generations normally had political resources. The political resources means they have the rights to control the distribution of money. They used the money to buy the relationships (connections) then any company they want to get in, is very easy.”
Many netizens commented about the multinational pharmaceutical scandals.
Some netizens said, “No matter how good foreign companies are, once they enter China they become polluted.” A netizen said: “Power is invincible, if a company is national or multinational, all controlled by Red second and third generation.”
Some netizens are dissatisfied with the so-called “healthcare reforms” that were carried out by the CCP in recent years..
Xinjiang Netizen Mr. Zhang: “They use unauthorized policies. Then through agencies operated by the privileged and princelings groups, they increase the price of medicines. Although the state health benefit can reimburse some costs, the civilians' cost burdens increased several times higher.”
Sources said that multinational pharmaceutical companies were established in China 30 years ago. Behind the US and Japan, China now is the third biggest pharmaceutical market in the world. Nevertheless, this market is full of fraud and self-interest chains due to the CCP's corrupt system.
Gong Shengli: “Chinese society allows the existence of such corruption. Especially for the CCP's cadres. If you are a CCP cadre, one almost talks in an authoritative way. There is no environment for checks and balances. There is no place for this under citizens' monitoring.”
Gong Shenli said in the past, the CCP mentioned “rule of law”. However, now the authorities have stressed the party governance. It will naturally put “rule of law” aside, making the country of men more powerful, so the corruption is much worse.
大陸媒體《證券市場週刊》最近披露了一份資料，羅列了部分在華跨國藥企的高管名單。其中，家世顯赫的李振福2003年加盟諾華公司任中國區總裁，此後諾華中國區的增長速度高達諾華全球增速的3倍。2012年接任諾華中國區總裁的徐海瑛則有一個家族背景很深的丈夫。
在這些跨國藥企的高管中，有些人還曾擔任過中共政協委員和人大代表。
馮丹龍，現任美國輝瑞製藥中國企業事務部總監、公司發言人，曾擔任全國政協委員、上海市人大代表。馮丹龍的姑姑馮理達是國內外著名免疫學專家，奶奶李德全則是中共建政後的首任衛生部部長。
大陸企業觀察員何軍樵向《新唐人》表示，中國大陸是一個專制的市場經濟社會，和其他自由社會的經濟形式都不一樣。
大陸企業觀察員何軍樵：「在這樣一個權力主導下的經濟結構裡面，經濟尋求與權力的這種合作，那是很自然的一個事情。所以運用這些高乾子弟，實際上也是考慮到他們背後的家庭背景關係。」
《證券市場週刊》的報導指出，跨國藥企在中國的經營已經披上政治色彩。跨國公司要想在中國新設或者併購企業等都需要各級政府部門的審批登記。因此，跨國藥企為了自身的經營和安全考慮，便把政府關係作為一項最主要工作，每年撥出大筆費用進行政府公關。於是，在這些跨國藥企負責與政府打交道的部門中，就出現了各種有深厚背景的人物。
北京國情內參首席研究員、獨立中國問題學家鞏勝利：「因為中國是一個人治的國家。人家說的紅二代、紅三代，一般都掌握有政治資源，政治資源簡單的說，就是批錢。那麼他一句話，通過他的關係（錢）進去到哪個企業，這都是很簡單的一件事。」
大陸網絡上，很多網民也對跨國藥企風波深有感觸。
有網友表示：再好的外企進入中國都會變質。網友寫道：權力迷藥天下無敵，無論本國、跨國（企業），盡入二代三代之手。
也有網友對中共當局近年進行的所謂「醫療改革」表示不滿。
新疆網友張先生：「它盛行潛規則。然後它通過中共權貴階層、太子黨代理以後，把藥價提得很高，即使國家給報銷一部分，老百姓的負擔也是比醫療改革以前還是增加了幾倍的負擔。」
據悉，跨國製藥企業進入中國已超過30年，目前，中國是僅次於美國和日本的全球第三大藥品市場。但這個市場卻因為中國的黨政體製而處處充滿腐敗的利益鏈條。
鞏勝利：「因為中國的社會允許這種腐敗存在，特別是黨政幹部。你像是黨的幹部，幾乎是說話一言九鼎，它沒有社會的製衡環境，沒有老百姓的監督環境。」
北京獨立中國問題學家鞏勝利指出，以前中共還提到過所謂「法治國家」，現在當局則一直在強調要加強黨治。而加強黨治自然就會把法治放到一邊，使人治更加強盛，腐敗更加嚴重。
採訪/朱智善 編輯/李謙 後製/王明宇
Multinational Pharmaceutical Companies in China Benefit Privilege Group
The corruption scandal of foreign pharmaceutical companies in China has intensified. Since the arrests of four senior managers at the world's leading pharmaceutical company GlaxoSmithKline,, AstraZeneca, Sanofi and Eli Lilly companies experienced similar scandals.
According to media reports, after multinational pharmaceutical companies enter China, they soon “do what Romans do”. They get keen on gray marketing practices. They recruit high-ranking officials' children to operate their businesses.
China's Capital Week magazine listed senior managers in multinational pharmaceutical companies in China. Among them, the distinguished lineage of Li Zhenfu (Jeffrey Li) joined Novartis in 2003, serving as China region President. Soon, the Novartis growth rate in China increased three times higher than the Novartis global market. In 2012, Xu Haiying became the Novartis president in China. Xu's husband came from a family with a connected background.
Among the list, some people in the past were members of the national committee and the National People's Congress
Feng Danlong currently serves as Affairs Director and spokesman of the US Pfizer China Corporate. Feng was a member of China's National Committee and a representative of Shanghai People's Congress. Feng's aunt Feng Lida was a famous immunology expert at home and abroad. Feng's grandmother, Li Dequan was the first Health Minister after the Chinese Communist Party (CCP) took over China.
He Junjiao, an enterprise observer in Mainland China told NTD that China is a society with authoritarian market. It has a different form comparing to free societys' economy.
He Junqiao: “Under such an economic structure, the economy latches onto the power becomes a natural outcome. Using high-ranking officials' children, actually is associated with their family background.”
Capital Week reported that multinational pharmaceutical companies in China have been involved in political affairs. If they want to set up or purchase a new company in China, they need CCP approval. Considering this point, they allocate relations with the CCP as their top priority work. They spend large amount of money on government relations. So these multinational pharmaceutical companies recruited people with well connected CCP backgrounds.
Gong Shenli, independent China affairs expert:“China is a country of men. The Red second and third generations normally had political resources. The political resources means they have the rights to control the distribution of money. They used the money to buy the relationships (connections) then any company they want to get in, is very easy.”
Many netizens commented about the multinational pharmaceutical scandals.
Some netizens said, “No matter how good foreign companies are, once they enter China they become polluted.” A netizen said: “Power is invincible, if a company is national or multinational, all controlled by Red second and third generation.”
Some netizens are dissatisfied with the so-called “healthcare reforms” that were carried out by the CCP in recent years..
Xinjiang Netizen Mr. Zhang: “They use unauthorized policies. Then through agencies operated by the privileged and princelings groups, they increase the price of medicines. Although the state health benefit can reimburse some costs, the civilians' cost burdens increased several times higher.”
Sources said that multinational pharmaceutical companies were established in China 30 years ago. Behind the US and Japan, China now is the third biggest pharmaceutical market in the world. Nevertheless, this market is full of fraud and self-interest chains due to the CCP's corrupt system.
Gong Shengli: “Chinese society allows the existence of such corruption. Especially for the CCP's cadres. If you are a CCP cadre, one almost talks in an authoritative way. There is no environment for checks and balances. There is no place for this under citizens' monitoring.”
Gong Shenli said in the past, the CCP mentioned “rule of law”. However, now the authorities have stressed the party governance. It will naturally put “rule of law” aside, making the country of men more powerful, so the corruption is much worse.
